글루코스 바이오센서 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Glucose Biosensors Market size is expected to reach USD 24.05 Billion in 2034 from USD 11.17 Billion (2025) growing at a CAGR of 8.89% during 2026-2034.

The glucose biosensors market is undergoing rapid advancement as continuous glucose monitoring and wearable technologies transform diabetes management. The demand for real-time, accurate, and minimally invasive glucose measurement devices is intensifying due to rising prevalence of diabetes and metabolic disorders globally. Innovative biosensors employing electrochemical, optical, and enzymatic detection mechanisms are enhancing sensitivity, reducing measurement errors, and providing actionable health insights. Integration with mobile applications and cloud platforms enables personalized disease management and predictive analytics for better glycemic control.

Technological convergence is expanding market possibilities. Miniaturization, flexible electronics, and non-invasive sensing techniques such as sweat or interstitial fluid analysis are improving patient comfort and adherence. AI algorithms embedded in biosensor platforms provide predictive alerts, trend analysis, and data-driven recommendations, while sensor durability and biocompatibility improvements are extending device life. These developments are particularly relevant in remote healthcare, telemedicine, and home diagnostics, where timely intervention is critical. Partnerships between medical device innovators, digital health startups, and pharma companies are accelerating product innovation cycles and market penetration.

The market's future is strongly influenced by personalized healthcare and chronic disease management trends. Rising demand for integrated healthcare ecosystems, combined with government support for diabetes prevention and monitoring programs, is driving adoption across developed and emerging economies. Advances in point-of-care diagnostics, wearable patch systems, and continuous monitoring platforms are likely to expand application beyond traditional diabetes management into fitness, preventive care, and metabolic research. As technology adoption deepens, glucose biosensors will become essential instruments in proactive health management, combining precision, accessibility, and predictive capability.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Electrochemical Biosensor
• Optical Biosensor
• Others

By End-use

• Hospitals
• Homecare
• Diagnostic Center

COMPANIES PROFILED

• Abbott, Dexcom Inc, Ascensia Diabetes Care Holdings AG, Nova Diabetes Care, F HoffmannLa Roche Ltd, Sanofi, GlySens Incorporated, Trividia Health Inc, Bayer AG, LifeScan IP Holdings, PalmSens
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GLUCOSE BIOSENSORS MARKET: BY TYPE 2022-2034 (USD MN and K Units)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Electrochemical Biosensor Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)
• 4.3. Optical Biosensor Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)

Chapter 5. GLOBAL GLUCOSE BIOSENSORS MARKET: BY END-USE 2022-2034 (USD MN and K Units)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)
• 5.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)
• 5.4. Diagnostic Center Estimates and Forecasts By Regions 2022-2034 (USD MN and K Units)

Chapter 6. GLOBAL GLUCOSE BIOSENSORS MARKET: BY REGION 2022-2034(USD MN and K Units)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and K Units)
  • 6.2.1 By Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and K Units)
  • 6.3.1 By Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and K Units)
  • 6.4.1 By Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and K Units)
  • 6.5.1 By Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and K Units)
  • 6.6.1 By Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL GLUCOSE BIOSENSORS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Dexcom Inc
  • 8.2.3 Ascensia Diabetes Care Holdings AG
  • 8.2.4 Nova Diabetes Care
  • 8.2.5 F. Hoffmann-La Roche Ltd
  • 8.2.6 Sanofi
  • 8.2.7 GlySens Incorporated
  • 8.2.8 Trividia Health Inc
  • 8.2.9 Bayer AG
  • 8.2.10 LifeScan IP Holdings
  • 8.2.11 PalmSens